Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia

Purpose

The investigators postulate that Pevonedistat will be effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) when combined with a standard backbone ALL chemotherapy regimen.

Eligibility

  • Ages: 16 to 39
  • Sexes: All
  • Accepts healthy volunteers?: No

For additional eligibility criteria, please contact the study team.

Procedures

This is a phase I study of the addition of pevonedistat to induction chemotherapy for AYA patients (16-39 years of age) with relapsed/refractory ALL utilizing a traditional 3+3 design with dose expansion cohort of 6 patients. Starting dose level for pevonedistat is 15 mg/m2.

If the number of dose-limiting toxicities (DLTs) is greater than 1 out of 3 patients in the starting dose level, next dose level is 10 mg/m2 (dose level -1). Chemotherapy will consist of pevonedistat in combination with a standard VXLD regimen. The duration of each cycle will be 29 days.

Contact the study team

Additional eligibility criteria and study procedure details can be explained by the study team. Please call or email:

Phone: 352.273.9126
Email: slaytwb@peds.ufl.edu

Gender

Male
Female

Keywords

Acute lymphoblastic leukemia, Leukemia, Chronic lymphocytic leukemia, Chemotherapy

Principal Investigator

William Slayton, MD

Department

Oncology

Contact Information

slaytwb@peds.ufl.edu

352.273.9126


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at CTSI-Studies-L@lists.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams